Renaud Prudent

Ph.D., Screening Technologies

Renaud joined Edelris in 2018 as the Manager of the Screening Technologies Unit, where he pioneered the development of AS-MS technologies. Prior to this, Renaud served as the chief operating officer at Cellipse, a drug discovery start-up company that he co-founded.

During his post-doc time, Renaud developed and applied different screening approaches in the oncology area, for example synthetic lethality and drug enhancers.

He obtained a Ph.D. in chemical biology from the Université Grenoble Alpes, where he worked on the screening of allosteric kinase inhibitors. He has co-authored over 25 publications and patents.